SG
ICPT

Societe Generale’s Intercept Pharmaceuticals, Inc. ICPT Stock Holding History

Societe Generale’s Portfolio ICPT Stock Details ICPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		$1.7M Buy
+11,894
New +$1.73M 0.01% 946

Other funds holding ICPT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
CG
Carmignac Gestion Paris, France $6.51B AUM 19.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
HCM
Highfields Capital Management Boston, Massachusetts $68.3M AUM 21.64% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Societe Generale's ICPT Position: Q2 2016 in Review

Societe Generale opened a new position in Intercept Pharmaceuticals, Inc. (ICPT) in Q2 2016: 11,894 shares worth $1.7M. The stake represents 0.01% of the portfolio and ranks #946 among its holdings.

167 funds tracked by Wall St. Rank hold ICPT as of Q2 2016.

  • Societe Generale held 11,894 shares of Intercept Pharmaceuticals, Inc. worth $1.7M as of Q2 2016.
  • Intercept Pharmaceuticals, Inc. was a new Societe Generale position in Q2 2016.
  • Intercept Pharmaceuticals, Inc. made up 0.01% of Societe Generale's portfolio in Q2 2016, its #946 holding.
  • 167 funds tracked by Wall St. Rank held Intercept Pharmaceuticals, Inc. as of Q2 2016.

Based on Societe Generale's 13F filing for Q2 2016, filed 2 Aug 2016.